Clinical Trial Update: Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating alloreactive haploidentical natural killer cells with busulfan and fludarabine/ATG conditioning in leukemia, including chronic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Leukemia

Drugs mentioned

• Anti-thymocyte globulin (ATG) (anti-thymocyte globulin)
• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2015-12-31